Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virological and Immunological Assessment in HIV Positive Participants on 2DR Versus 3DR
NCT04553081Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- May 2020
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Difference in amount of intact replication-competent HIV-1 sequences in CD4 cells at 48 weeks. Started May 2020; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04553081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553081.